从早期药物治疗到近期药物干预:急性冠脉综合征管理进展
本文回顾了急性冠脉综合征(ACS)药物治疗与介入策略的关键历史试验。斑块破裂血栓形成是治疗靶点,从卧床等待到立即药物再灌注、长期阿司匹林,再到PCI支架和P2Y12抑制剂强化抗血小板,联合抗凝、他汀和神经激素抑制进一步降低死亡和新发心梗,1年死亡率从1995年约22%降至2014年约11%。
要点
- 斑块破裂血栓形成是ACS治疗策略的核心靶点
- 药物再灌注+长期阿司匹林、PCI支架+P2Y12抑制剂、抗凝/他汀/神经激素抑制逐步改善预后
- 联合药物与介入策略使1年死亡率从1995年约22%降至2014年约11%
核心结论
- 联合药物与介入治疗策略显著降低了ACS患者1年死亡率,从1995年约22%降至2014年约11%。
研究设计与样本
- 本文为JACC state-of-the-art综述,梳理ACS药物治疗与介入策略的历史和关键试验证据。
主要发现
- 斑块破裂伴血栓形成及冠状动脉闭塞或远端栓塞是ACS治疗策略的关键靶点。
- 1980年代起,立即药物再灌注和长期阿司匹林替代了传统卧床等待策略。
- 2000年代初起,PCI支架机械再灌注和P2Y12抑制剂强化血小板抑制进一步改善预后。
- 辅助抗凝、他汀和神经激素抑制治疗进一步降低死亡率和预防新发心梗。
临床怎么用
- ACS管理应联合药物与介入策略,包括及时再灌注、抗血小板、抗凝、他汀和神经激素抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This focus seminar will take the reader through the history and pivotal trials that have formed the current state-of-the-art management for acute coronary syndromes. The identification of a ruptured plaque with thrombus formation and subsequent occlusion or downstream embolization in the coronary artery was the key to developing new and effective treatment strategies. The traditional wait-and-see approach with prolonged bedrest was replaced in the 1980s by immediate pharmacological reperfusion of the occluded coronary artery and long-term aspirin to prevent reinfarction. Mechanical reperfusion with percutaneous coronary intervention with stenting and more intense platelet inhibition with P2Y12 inhibitors further improved outcomes from early 2000s. Adjunctive treatment regimens, including anticoagulants, statins, and neurohormonal inhibition, were found to further reduce mortality and prevent new infarctions. Taken together, the use of new combined pharmacological and interventional treatment strategies has led to a remarkable decrease in 1-year mortality from around 22% in 1995 to around 11% by 2014.
引用
- Szummer K, Jernberg T, Wallentin L, et al. From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019. PMID: 31537272. doi:10.1016/j.jacc.2019.03.531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。